Q1 2025 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Key Points
- The U.S. FDA has cleared Brainstorm Cell Therapeutics Inc (BCLI) to initiate a pivotal Phase 3b trial for NurOwn, marking a significant milestone in their ALS treatment development.
- The trial design has been agreed upon with the FDA under a special protocol assessment (SPA), which de-risks the regulatory pathway for NurOwn.
- Brainstorm Cell Therapeutics Inc (BCLI) has secured a leading U.S. clinical site that has passed FDA inspection, enhancing their operational readiness for the upcoming trial.
- The company is actively engaged in negotiations with approximately 15 leading clinical centers across the United States for the Phase 3b trial, indicating strong interest from the ALS research community.
- Brainstorm Cell Therapeutics Inc (BCLI) is pursuing multiple funding avenues, including a promising $15 million non-dilutive grant, to ensure the timely commencement of the trial.
- The company faces significant financial constraints, which are common in the biotech industry, and securing proper funding is essential to commence the trial.
- The initiation and successful execution of the clinical trial demand a robust and sustainable cash flow, which is currently a challenge for Brainstorm Cell Therapeutics Inc (BCLI).
- The company has not yet signed clinical trial agreements (CTAs) with the clinical centers, which could delay the trial's start.
- The manufacturing capacity at the Tel Aviv facility is limited, and the company is still in the process of expanding its manufacturing footprint to the United States.
- The exosome program, while promising, is still in the preclinical stage and requires strategic partnerships to advance towards clinical development.
Greetings and welcome to the Brainstorm Cell Therapeutics first-quarter 2025 conference call. At this time, all participants are on a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Joyce Lonergan of LifeSci Advisors. Joyce, you may begin.
Thank you, Holly. Good morning and thank you for joining us today.
Before passing the call to company management for prepared remarks, I would like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics, and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS; the sufficiency of the company's existing capital resources for continuing operations in 2025 and beyond; the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn, and related
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
